Start Submission Become a Reviewer

Reading: Ocular Manifestation of CACNA1A Pathogenic Variants

Download

A- A+
Alt. Display

Genetic Disorders

Ocular Manifestation of CACNA1A Pathogenic Variants

Authors:

Karit Reinson,

Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia; Department of Paediatrics, Institute of Clinical Medicine, University of Tartu, Tartu, EstoniaNone
X close

Katrin Õunap

Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia; Department of Paediatrics, Institute of Clinical Medicine, University of Tartu, Tartu, EstoniaNone
X close

Abstract

Investigators from The Children’s Hospital at Westmead in New South Wales; The Queensland University of Technology in Brisbane; Sydney Children’s Hospital in New South Wales and Laboratoire de Genetique in Paris investigated children with a proven heterozygous missense pathogenic variant in the CACNA1A gene.
How to Cite: Reinson, K. and Õunap, K., 2016. Ocular Manifestation of CACNA1A Pathogenic Variants. Pediatric Neurology Briefs, 30(12), p.46. DOI: http://doi.org/10.15844/pedneurbriefs-30-12-2
9
Downloads
2
Twitter
  Published on 01 Dec 2016
 Accepted on 11 Oct 2016            Submitted on 19 Sep 2016

Investigators from The Children’s Hospital at Westmead in New South Wales; The Queensland University of Technology in Brisbane; Sydney Children’s Hospital in New South Wales and Laboratoire de Genetique in Paris investigated children with a proven heterozygous missense pathogenic variant in the CACNA1A gene. The CACNA1A gene encodes the alpha-1 subunit of the voltage-gated calcium channel. Expression of these channels is particularly high in neuronal tissue, especially in the cerebellum. The literature on CACNA1A disorders in children is relatively modest, and the focus of the range of ocular presentations in childhood remains rare. The authors reviewed retrospectively nine children from Children’s Hospital at Westmead over a 10-year period (2005–2015). All of them had confirmed heterozygous mutation in the CACNA1A gene. Eye movement disorders like paroxysmal tonic upgaze (PTU), strabismus, and abnormal saccades were the presenting feature in eight of the nine children. There was a wide range in the age of presentation of the first sign (2mo–10y), though six of the nine children demonstrated the eye movement disorder in the first 2 years of life. None of them followed a ‘benign’ course. The children presenting with ocular abnormalities had additional problems including hypotonia, cerebellar ataxia, or epilepsy. Six patients were diagnosed with global developmental delay within 2 years of their initial presentation, including all three patients with PTU. In total, 5 patients had an abnormal brain MRI - cerebellar or generalized mild cerebral atrophy. Based on the previously described findings, the authors suggest that an eye movement disorder may be a clue to the underlying mutation in the CACNA1A gene, especially if there is evidence of developmental delay or cerebellar or cerebral atrophy on MRI. [1]

COMMENTARY. This interesting overview of children with heterozygous missense pathogenic variants in the CACNA1A gene gives a new perspective on the disease course. Since the concept of a ‘pre-symptomatic’ eye movement disorder was previously described in children [2, 3] and adults diagnosed with SCA6 [4], the suggestion that all children with PTU, and an ocular motor apraxia or strabismus (especially when associated with developmental delay or cerebellar atrophy), should be considered for CACNA1A genetic testing.

Importantly, a study like this calls attention to the wide phenotypic spectrum of patients with CACNA1A mutations. Moreover, we have recently described two sibs with bi-allelic CACNA1A pathogenic variants, which cause early onset epileptic encephalopathy, cerebral, cerebellar atrophy and optic nerve atrophy [5]. All this additional information could lead to better counselling regarding the prognosis at the time of diagnosis (e.g. episodes of severe hemiplegic migraine) as well as implementing more targeted therapies like verapamil [6].

As the authors pointed out, the weakness of their study is that it is retrospective with small number of patients and quite short period of follow-up. A multicenter research study with gene sequencing of all children with aforementioned eye movement disorders would identify the true frequency of the CACNA1A pathogenic variants in this cohort.

Disclosures

The author(s) have declared that no competing interests exist.

References

  1. Tantsis, EM Gill, D Griffiths, L Gupta, S Lawson, J Maksemous, N et al. (2016). Eye movement disorders are an early manifestation of CACNA1A mutations in children. Dev Med Child Neurol Jun 201658(6): 639–44, DOI: https://doi.org/10.1111/dmcn.13033 [PubMed]  

  2. Kipfer, S Jung, S Lemke, JR Kipfer-Kauer, A Howell, JP Kaelin-Lang, A et al. (2013). Novel CACNA1A mutation(s) associated with slow saccade velocities. J Neurol Dec 2013260(12): 3010–4, DOI: https://doi.org/10.1007/s00415-013-7099-4 [PubMed]  

  3. Roubertie, A Echenne, B Leydet, J Soete, S Krams, B Rivier, F et al. (2008). Benign paroxysmal tonic upgaze, benign paroxysmal torticollis, episodic ataxia and CACNA1A mutation in a family. J Neurol Oct 2008255(10): 1600–2, DOI: https://doi.org/10.1007/s00415-008-0982-8 [PubMed]  

  4. Christova, P, Anderson, JH and Gomez, CM (2008). Impaired eye movements in presymptomatic spinocerebellar ataxia type 6. Arch Neurol Apr 200865(4): 530–6, DOI: https://doi.org/10.1001/archneur.65.4.530 [PubMed]  

  5. Reinson, K Õiglane-Shlik, E Talvik, I Vaher, U Õunapuu, A Ennok, M et al. (2016). Biallelic CACNA1A mutations cause early onset epileptic encephalopathy with progressive cerebral, cerebellar, and optic nerve atrophy. Am J Med Genet A Aug 2016170(8): 2173–6, DOI: https://doi.org/10.1002/ajmg.a.37678 [PubMed]  

  6. Yu, W and Horowitz, SH (2003). Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology Jan 200360(1): 120–1, DOI: https://doi.org/10.1212/01.WNL.0000042051.16284.70 [PubMed]  


comments powered by Disqus